Receptor-specific regulation of B-cell susceptibility to Fas-mediated apoptosis and a novel Fas apoptosis inhibitory molecule

Immunological Reviews

Volumn 176, Issue , 2000, Pages 116-133

  Rothstein, T L ^a   Zhong, X ^a   Schram, B R ^a   Negm, R S ^a   Donohoe, T J ^a   Cabral, D S ^a   Foote, L C ^a   Schneider, T J ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; INTERLEUKIN 4 RECEPTOR; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; PROTEIN TYROSINE KINASE;

ANIMAL CELL; APOPTOSIS; B LYMPHOCYTE; CELL CYCLE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033821799     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2000.00616.x     Document Type: Review

References (175)

1. Apoptosis by death factor
2. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
3. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
4. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
5. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
6. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
7. Monoclonal antibody-mediated tumor regression by induction of apoptosis
8. Expression of the Fas ligand in cells of T cell lineage
9. Xenospecific cytotoxic T lymphocytes use perforin- and Fas-mediated lyric pathways
10. Mechanism and biological significance of CD4-mediated cytotoxicity
11. Fas-mediated cytotoxicity by freshly isolated natural killer cells
12. Fas involvement in cytotoxicity mediated by human NK cells
13. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells
14. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
15. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
16. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
17. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
18. Fas gene mutations in the Canale-Smith syndrome an inherited lymphoproliferative disorder associated with autoimmunity
19. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease
20. Clinical, immunological and pathological consequences of Fas-deficient conditions
21. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
22. Fas and Fas ligand: Lpr and gld mutations
23. Autoimmunity as a consequence of retrovirus-mediated expression of C- FLIP in lymphocytes
24. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
25. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
26. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions
27. + T cell-mediated cytotoxicity
28. + cytotoxic T cells
29. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells
30. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells
31. Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny
32. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation
33. Inducible nuclear expression of NF-κB in primary B cells stimulated through the surface Ig receptor
34. Cross-linking of surface IgM activates NF-κB in B lymphocyte
35. Cross-linking of surface Ig receptors on routine B lymphocytes stimulates the expression of nuclear tetradecanoyl phorbol acetate-response element-binding proteins
36. T cell-dependent induction of NF-κB in B cells
37. Cyclosporin-A sensitive induction of NF-AT in murine B cells
38. Cross-linking CD40 on B cells rapidly activates nuclear factor-κB
39. Induction of the transcription factors NF-κB, AP-1 and NF-AT during B cell stimulation through the CD40 receptor
40. Receptor-specific induction of individual AP-1 components in B lymphocytes
41. CD40, but not lipopolysaccharide and anti-IgM stimulation of primary B lymphocytes, leads to a persistent nuclear accumulation of RelB
42. Receptor-specific induction of NF-κB components in primary B cells
43. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells
44. Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells
45. Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded
46. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway
47. Fas ligation induces apoptosis of CD40-activated human B lymphocytes
48. Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis
49. Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor
50. IL-4 induces Fas resistance in B cells
51. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes
52. 39kDa Protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells
53. Molecular and biological characterization of a murine ligand for CD40
54. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
55. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
56. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
57. Fas ligand mediates activation-induced cell death in human T lymphocytes
58. Fas (CD95)/Fas ligand interactions regulate antigen-specific major histocompatibility complex-restricted T/B cell proliferative responses
59. + B cells
60. The role of clonal selection and somatic mutation in autoimmunity
61. Oligoclonality of rheumatoid factors arising spontaneously in lpr/lpr mice
62. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation
63. + T cells
64. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice
65. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells
66. Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions
67. + T cells
68. Humoral immune functions in IL-4 transgenic mice
69. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome
70. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice
71. + T cells
72. Association of interleukin-4 plasma levels with traumatic injury and clinical course
73. Isoquinolinesulfonamides novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C
74. Antigen and helper T lymphocytes activate B lymphocytes by distinct signaling pathways
75. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells
76. Antigen-receptor engagement in B cells induces nuclear expression of STAT5 and STAT6 proteins that bind and transactivate an IFN-γ activation site
77. Activation and proliferation signals in mouse B cells. VIII. Induction of DNA synthesis in B cells by a combination of calcium ionophores and phorbol myristate acetate
78. Stimulation of murine B cells by the combination of calcium ionophore plus phorbol ester
79. A novel mechanism for rescue of B cells from CD95/Fas-mediated apoptosis
80. Regulation of inducible gene expression by the transcription factor NF-κB
81. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
82. NF-κB regulates Fas/APO-1/CD95- and TCR-mediated apoptosis of T lymphocytes
83. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNF-α-induced apoptosis
84. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis
85. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes
86. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
87. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
88. Proteasome regulation of Fas ligand cytotoxicity
89. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells
90. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence
91. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling
92. Molecular thanatopsis: A discourse on the BCL2 family and cell death
93. Cloning and molecular characterization of mouse bcl-x in B and T lymphocytes
94. Bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice
95. Bcl-x protects primary B cells against Fas-mediated apoptosis
96. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis
97. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death
98. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents
99. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat
100. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide
101. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
102. Inhibition of death receptor signals by cellular FLIP
103. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis
104. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis
105. CASH, a novel caspase homologue with death effector domains
106. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP
107. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2
108. Transcriptional activation of the tumor necrosis factor α-inducible zinc finger protein, A20, is mediated by κB elements
109. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity
110. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia
111. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
112. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins
113. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death
114. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival
115. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
116. Activation of mouse lymphocytes by anti-immunoglobulin. I. Parameters of the proliferative response
117. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice
118. Defective B cell development and function in Btk-deficient mice
119. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
120. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex
121. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
122. A novel gene coding for a Fas apoptosis inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes
123. Protein kinase C activation blocks anti-IgM-mediated signaling BAL17 B lymphoma cells
124. Egr-1 expression in surface Ig-mediated B cell activation. Kinetics and association with protein kinase C activation
125. Surface Ig receptor-induced nuclear AP-1-dependent gene expression in B lymphocytes
126. Yama/CPP32-β, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase
127. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
128. Second-messenger pathways involved in the regulation of survival in germinal-centre B cells and in Burkitt lymphoma lines
129. Radiation-induced apoptosis in a murine T-cell hybridoma
130. The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme
131. C elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2
132. The IM. AGE. Consortium: An integrated molecular analysis of genomes and their expression
133. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia
134. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization
135. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung
136. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: A pre-B-cell lymphoma model
137. Bcl-2 obstructs negative selection of autoreactive, hypermutated antibody V regions during memory B cell development
138. B lymphocytes from the autoimmune-prone mouse strain MLR/lpr manifest an intrinsic defect in tetraparental MRL/lpr in equilibrium DBA/2 chimeras
139. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice
140. Activation interferes with the APO-1 pathway in mature human T cells
141. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis
142. Expression of Bcl-2, and Bax after T cell activation and IL-2 withdrawal
143. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex
144. The role of c-FLIP in modulation of CD95-induced apoptosis
145. Mechanisms of peripheral T cell deletion: Anergized T cells are Fas resistant but undergo proliferation-associated apoptosis
146. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death
147. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2 effectors undergo rapid Fas/FasL-mediated apoptosis
148. Differential ability of T cell subsets to undergo activation-induced cell death
149. TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis
150. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells
151. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia
152. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis
153. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis
154. FADD expression and caspase activation in B-cell lymphomas resistant to Fas-mediated apoptosis
155. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness
156. Resistance to Fas-mediated apoptosis in human hepatoma cells
157. Fas expression and function in normal and malignant breast cell lines
158. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
159. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
160. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis
161. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice
162. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia
163. Fas and Fas ligand interactions suppress melanoma lung metastasis
164. Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells
165. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-γ
166. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis
167. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
168. Two CD95 (APO-1/Fas) signaling pathways
169. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
170. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
171. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen
172. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
173. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
174. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
175. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex